Abivax has filed a patent for the treatment and prevention of Coronaviridae infections in humans. The patent includes compounds, pharmaceutical compositions, and medicaments for treating and preventing these infections, as well as methods for assessing the infection or the efficacy of treatment. GlobalData’s report on Abivax gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Abivax, cancer treatment biomarkers was a key innovation area identified from patents. Abivax's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment or prevention of coronaviridae infection in humans
A recently filed patent (Publication Number: US20230142547A1) describes methods for treating or preventing Coronaviridae infections and related conditions. The patent claims involve administering specific compounds, referred to as formula (I) and formula (II), for therapeutic purposes.
The methods outlined in the patent involve the use of pharmaceutically acceptable salts of the compounds. These salts can be formed with inorganic acids or organic acids, and there are various specific salts listed in the patent, including adipate, ascorbate, benzoate, citrate, formate, acetate, fumarate, and many others.
The patent specifies that the methods are applicable to different types of Coronaviridae, including Letovirinae and Orthocoronavirinae. Within these subfamilies, the methods can be used for Alphacoronavirus, Betacoronavirus, Deltacoronavirus, and Gammacoronavirus. Furthermore, the methods can be applied to specific genera within these subfamilies, such as Embecovirus, Hibecovirus, Merbecobivirus, Nobecovirus, and Sarbecovirus.
Specifically, the methods can be used for treating Coronaviridae infections caused by Sarbecovirus, particularly those related to Severe Acute Respiratory Syndrome (SARS). The patent lists several SARS-related coronaviruses, including SARS-CoV, SARSr-CoV WIV1, SARSr-CoV HKU3, SARSr-CoV RP3, and SARS-CoV-2 (the virus responsible for the COVID-19 pandemic).
The patent also mentions that the methods can be used for conditions related to Coronaviridae infections, such as pulmonary fibrosis, vasculitis, Kawasaki disease, and tissue damage or destruction.
In addition to the administration of the compounds, the patent describes methods for measuring the level of the compound in various samples from the patient, such as blood, plasma, tissue, saliva, and serum. The presence and expression level of a specific microRNA, miR-124, can also be measured in blood and tissue samples to assess the efficacy of the treatment or the presence of a Coronaviridae infection.
The patent further includes methods for assessing Coronaviridae infections in patients by measuring the presence or expression level of miR-124 in biological samples and comparing it to a control reference value.
Overall, the patent presents a range of methods for treating and preventing Coronaviridae infections and related conditions, with specific compounds and measurement techniques outlined. These methods have potential applications in the ongoing efforts to combat the COVID-19 pandemic and other Coronaviridae infections.
To know more about GlobalData’s detailed insights on Abivax, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
